A Leader in Rapid Point-of-Care Diagnostics.
Introducing ID NOW™ COVID-19 rapid POC test
The ID NOW™ COVID-19 assay is now available under U.S. Food and Drug Administration Emergency Use Authorization (EUA). High-quality molecular positive results in as little as 5 minutes, targeting COVID-19 RdRp Gene. *Emergency use only. Click on product information link below for more information on EUA.Product information
Our commitment to address the COVID-19 pandemic
As the world leader in point-of-care diagnostics, Abbott is adding its expertise and scale to help fight the COVID-19 global pandemic.Learn more
The first-ever POC HbA1c test cleared for diagnosis
Finally, an HbA1c test that can be used as an aid to diagnose and monitor patients with diabetes or pre-diabetes at the point of care.Discover diagnosis in minutes
Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes
Read the press release to find out more.
See how ID NOW™ instrument works
Learn how Abbott utilizes unique isothermal nucleic acid amplification technology.
Our best tech to help slow COVID-19
The health and well-being of our customers and communities is our top priority. We are deploying our best tech to slow the speed and reach of coronavirus.
Point-of-care diagnostics is a growing and dynamic industry helping to improve clinical and economic outcomes globally. Abbott brings you a variety of expert viewpoints on new innovations, insights, and impacts that are shaping the future of diagnostics around the world.